Home Blog Page 3

Dates & Cities Announced for HOT ROD Power Tour & HOT ROD Drag Week Celebrating Route 66 in 2026

0

The mighty HOT ROD Power Tour and highly competitive HOT ROD Drag Week are back and heading to Route 66 in 2026! The two wildly popular traveling events will stop at several cities along the legendary highway.

The 32nd annual HOT ROD Power Tour will take place from June 8-12, 2026. The team is gearing up to hit five venues: Route 66 Raceway in Joliet, IL; Village of Rantoul in Rantoul, IL; World Wide Technology Raceway in St. Louis, MO; Missouri State University in Springfield, MO; and Tulsa Raceway Park in Tulsa, OK.

America’s largest traveling car show puts on display more than 6,000 cars and trucks of all years, makes, and models for tens of thousands of automotive enthusiasts and fans.

HOT ROD POWER TOUR 2026 SCHEDULE:

  • Kickoff / Day 1: June 8 – Route 66 Raceway, Joliet, IL
  • Day 2: June 9 – Village of Rantoul, Rantoul, IL
  • Day 3: June 10 – World Wide Technology Raceway, St. Louis, MO
  • Day 4: June 11 – Missouri State University, Springfield, MO
  • Day 5: June 12 – Tulsa Raceway Park, Tulsa, OK

Stay tuned for HOT ROD Power Tour Registration details coming in early 2026.

The 22nd annual HOT ROD Drag Week will take place from September 13-18, 2026. This year, the crew will take off from and end at Route 66 Raceway in Joliet, IL and hit several raceways in between: Byron Dragway in Byron, IL; Cordova Dragway in Cordova, IL; and World Wide Technology Raceway in St. Louis, MO.

The world’s toughest competition to find the ultimate street-legal drag car puts competitors through a grueling test over five days of action-packed drag racing, requiring racers to drive their vehicles on a specified route from city to city, approximately 1,000 miles, while securing the quickest possible elapsed time across the five days.

 HOT ROD DRAG WEEK 2026 SCHEDULE:

  • Tech Inspection, Registration, Test ‘N’ Tune – September 13 – Route 66 Raceway, Joliet, IL
  • Day 1: September 14 – Route 66 Raceway, Joliet, IL
  • Day 2: September 15 – Byron Dragway, Byron, IL
  • Day 3: September 16 – Cordova Dragway, Cordova, IL
  • Day 4: September 17 – World Wide Technology Raceway, St. Louis, MO
  • Finals / Day 5: September 18 – Route 66 Raceway, Joliet, IL

HOT ROD Drag Week registration opens in February – more details to come!

Connect:
For more information on HOT ROD Power Tour, visit hotrod.com/hot-rod-power-tour;
or connect on Facebook: facebook.com/hotrodmag; X: x.com/hotrodmagazine; and Instagram: www.instagram.com/hotrodmagazine

 For more information on HOT ROD Drag Week, visit hotrod.com/hot-rod-drag-week;
or connect on Facebook: facebook.com/hotrodmag; X: x.com/hotrodmagazine; and
Instagram: www.instagram.com/hotrodmagazine, and also use #hotroddragweek.

Electric Vehicle Collision Claims Rebound as Expiring U.S. Government Tax Incentives Drive Record Sales

0

Mitchell, a leader in the development of innovative auto physical damage technology solutions, today announced the availability of its latest Plugged-In: EV Collision Insights report. The Q3 2025 edition highlights a dramatic reversal in U.S. collision claims frequency for repairable battery electric vehicles (BEVs), which dropped for the first time in Q2 before rebounding last quarter to an all-time high of 3.21% just as expiring government tax incentives prompted record-breaking sales. BEV claims also jumped to 4.91% in Canada, a year-over-year increase of 24%.

“We’re witnessing the immediate impact of policy changes on BEV adoption and collision claim trends in both the U.S. and Canada,” said Ryan Mandell, Mitchell’s vice president of strategy and market intelligence. “With recent political and trade developments producing uncertainty, many automakers are now diversifying their portfolios to accommodate more hybrid and gasoline-powered alternatives as they reassess their BEV investments and growth targets. This gradual, geographically uneven transition to widespread vehicle electrification will require auto insurers and collision repairers to adjust underwriting strategies, business processes and workforce training to support a wider mix of drivetrains.”

The Q3 Plugged-In: EV Collision Insights report also reveals:

  • Claims Severity: Average severity for repairable BEVs dropped to $6,185 in the U.S. and $6,954 (CAD) in Canada, a decrease of 2.4% and 1.5% respectively from Q2. In both countries, automobiles with an internal combustion engine (ICE) had the lowest average severity followed by mild hybrid electric vehicles (MHEVs) and plug-in hybrid electric vehicles (PHEVs).
  • Claims Frequency by Region: Regions with the most BEVs per capita also continue to have the highest number of BEV collision claims. Last quarter, 8.74% of all repairable vehicle claims in British Columbia were for BEVs. Quebec came in a close second at 8.37% and California was third at 6.50%.
  • Total Loss Market Values: Total loss market values averaged $29,827 for BEVs, a decrease of approximately 1% from Q2, compared with $13,979 for ICE automobiles.
  • Parts Utilization: Without a robust alternate parts industry for BEVs, OEM parts are most frequently used in BEV collision repairs. On estimates, 85% of the parts dollars for repairable vehicles in Q3 were designated for OEM parts—a slight increase over the previous quarter—versus 62% for ICE alternatives.

Visit the Mitchell website to download the full report or access previous issues and subscribe to future publications from www.mitchell.com/plugged-in.

TrialAssure Officially Granted New Patent for Date Offset Anonymization Technology by U.S. Patent and Trademark Office

TrialAssure, a leading technology provider advancing clinical trial transparency, disclosure, and data sharing, announced today that it has been granted a utility patent by the United States Patent and Trademark Office (USPTO) for its proprietary date offset anonymization method. This breakthrough technology enhances data protection by streamlining the anonymization of subject-level dates in clinical trial documents.

The patent, titled “Date Offset in Document,” covers a method for anonymizing digital documents containing multiple subject-related dates. By applying a user-defined ruleset anchored to a specific date, the system modifies all subject-related dates using calculated offset values. This preserves the relative timing and data integrity needed for scientific analysis while safeguarding patient privacy. TrialAssure’s proprietary algorithm identifies subject-specific dates in unstructured text and classifies them, allowing the offset transformations to be applied correctly and efficiently across thousands of pages. In doing this, Sponsors are able to share documents with better scientific utility and ensure consistency with anonymized datasets.

“This patent award is further proof of the strength of our technology team and our long-term investment in developing smart, auditable anonymization processes that align with global data sharing requirements,” said Prasad M. Koppolu, Chief Operating Officer (COO) at TrialAssure. “We are proud to blend AI advancement with the right level of human knowledge to push boundaries globally and provide our customers with innovative tools that protect privacy and maintain utility.”

In addition to replacing subject-specific dates, the patented system provides a summary display of anchor dates, offsets, original dates, and their anonymized counterparts. This transparency enables better reviewer understanding, reproducibility, and regulatory confidence.

Strengthening the Market Position of TrialAssure ANONYMIZE

Koppolu added, “The issuance of this patent reinforces the expanding role of TrialAssure ANONYMIZE as a leading platform for compliant, high-utility anonymization. With a significant rise in usage across the pharmaceutical, biotechnology, and medical device sectors in recent years, organizations are increasingly choosing TrialAssure ANONYMIZE to meet the growing demand for speed, science, and flexibility in clinical trial data sharing.”

Key strengths of the platform include:

  • AI-guided automation backed by expert oversight to streamline redaction and anonymization of clinical documents and datasets
  • Support for global data sharing requirements, including EMA Policy 0070, Health Canada PRCI, EU CTR, and others
  • Centralized, real-time workbench that improves reviewer collaboration, decision tracking, and audit readiness
  • Transparent risk scoring and traceability that give users full visibility into decisions, offsets, and anonymized elements
  • Seamless integration with clinical trial disclosure workflows to reduce rework and increase submission efficiency
  • Use beyond pharma, in legal, finance, and transportation applications, among others

TrialAssure ANONYMIZE continues to grow as the preferred choice for Sponsors seeking a future-focused approach to data, document, and image anonymization and redaction technology, and the newly-patented technology further strengthens TrialAssure’s portfolio of AI-powered and expert-enabled solutions used by pharmaceutical, biotechnology, and medical device organizations across the globe. To learn more, visit https://www.trialassure.com/software/anonymize/.

Netflix to Acquire Warner Bros. Following the Separation of Discovery Global for $72.0 Billion

0

Today, Netflix, Inc. (the Company) and Warner Bros. Discovery, Inc. (WBD) announced they have entered into a definitive agreement under which Netflix will acquire Warner Bros., including its film and television studios, HBO Max and HBO.

The cash and stock transaction is valued at $27.75 per WBD share (subject to a collar as detailed below), with a total enterprise value of approximately $82.7 billion (equity value of $72.0 billion). The transaction is expected to close after the previously announced separation of WBD’s Global Networks division, Discovery Global, into a new publicly-traded company, which is now expected to be completed in Q3 2026.

This acquisition brings together two pioneering entertainment businesses, combining Netflix’s innovation, global reach and best-in-class streaming service with Warner Bros.’ century-long legacy of world-class storytelling. Beloved franchises, shows and movies such as The Big Bang Theory, The Sopranos, Game of Thrones, The Wizard of Oz and the DC Universe will join Netflix’s extensive portfolio including Wednesday, Money Heist, Bridgerton, Adolescence and Extraction, creating an extraordinary entertainment offering for audiences worldwide.

“Our mission has always been to entertain the world,” said Ted Sarandos, co-CEO of Netflix. “By combining Warner Bros.’ incredible library of shows and movies—from timeless classics like Casablanca and Citizen Kane to modern favorites like Harry Potter and Friends—with our culture-defining titles like Stranger Things, KPop Demon Hunters and Squid Game, we’ll be able to do that even better. Together, we can give audiences more of what they love and help define the next century of storytelling.” 

“This acquisition will improve our offering and accelerate our business for decades to come,” continued Greg Peters, co-CEO of Netflix. “Warner Bros. has helped define entertainment for more than a century and continues to do so with phenomenal creative executives and production capabilities. With our global reach and proven business model, we can introduce a broader audience to the worlds they create—giving our members more options, attracting more fans to our best-in-class streaming service, strengthening the entire entertainment industry and creating more value for shareholders.”

“Today’s announcement combines two of the greatest storytelling companies in the world to bring to even more people the entertainment they love to watch the most,” said David Zaslav, President and CEO of Warner Bros. Discovery. “For more than a century, Warner Bros. has thrilled audiences, captured the world’s attention, and shaped our culture. By coming together with Netflix, we will ensure people everywhere will continue to enjoy the world’s most resonant stories for generations to come.”

Combination Will Offer More Choice, More Opportunities, More Value 

  • Complementary strengths and assets: Warner Bros.’ studios are world-class, with Warner Bros. recognized as a leading supplier of television titles and filmed entertainment. HBO and HBO Max also provide a compelling, complementary offering for consumers. Netflix expects to maintain Warner Bros.’ current operations and build on its strengths, including theatrical releases for films.
  • More choice and greater value for consumers: By adding the deep film and TV libraries and HBO and HBO Max programming, Netflix members will have even more high-quality titles from which to choose. This also allows Netflix to optimize its plans for consumers, enhancing viewing options and expanding access to content.  
  • A stronger entertainment industry: This acquisition will enhance Netflix’s studio capabilities, allowing the Company to significantly expand U.S. production capacity and continue to grow investment in original content over the long term which will create jobs and strengthen the entertainment industry. 
  • More opportunities for the creative community: By uniting Netflix’s member experience and global reach with Warner Bros.’ renowned franchises and extensive library, the Company will create greater value for talent—offering more opportunities to work with beloved intellectual property, tell new stories and connect with a wider audience than ever before.
  • More value for shareholders: By offering members a wider selection of quality series and films, Netflix expects to attract and retain more members, drive more engagement and generate incremental revenue and operating income. The Company also expects to realize at least $2-3 billion of cost savings per year by the third year and expects the transaction to be accretive to GAAP earnings per share by year two.

Transaction Details and Timing

Under the terms of the agreement, each WBD shareholder will receive $23.25 in cash and $4.501 in shares of Netflix common stock for each share of WBD common stock outstanding at the closing of the transaction. The transaction values Warner Bros. Discovery at $27.75 per share, implying a total equity value of approximately $72.0 billion and an enterprise value of approximately $82.7 billion

In June 2025, WBD announced plans to separate its Streaming & Studios and Global Networks divisions into two separate publicly traded companies. This separation is now expected to be completed in Q3 2026, prior to the closing of this transaction. The newly separated publicly traded company holding the Global Networks division, Discovery Global, will include premier entertainment, sports and news television brands around the world including CNN, TNT Sports in the U.S., and Discovery, free-to-air channels across Europe, and digital products such as Discovery+ and Bleacher Report.  

The stock component is subject to a collar under which WBD shareholders will receive Netflix stock valued at $4.50 per share, provided the 15-day volume weighted average price (“VWAP”) of Netflix stock price (measured three trading days prior to closing) falls between $97.91 and $119.67. If the VWAP is below $97.91, WBD shareholders will receive 0.0460 Netflix shares for each WBD share. If the VWAP is above $119.67, WBD shareholders will receive 0.0376 Netflix shares for each WBD share.

The transaction was unanimously approved by the Boards of Directors of both Netflix and WBD. In addition to the completion of the separation of Discovery Global (WBD’s Global Networks business), completion of the transaction is subject to required regulatory approvals, approval of WBD shareholders and other customary closing conditions. The transaction is expected to close in 12-18 months.

Moelis & Company LLC is acting as Netflix’s financial advisor and Skadden, Arps, Slate, Meagher & Flom LLP is serving as legal counsel. Wells Fargo is acting as an additional financial advisor and, along with BNP and HSBC, is providing committed debt financing related to the transaction.  

Allen & Company, J.P. Morgan and Evercore are serving as financial advisors to Warner Bros. Discovery and Wachtell Lipton, Rosen & Katz and Debevoise & Plimpton LLP are serving as legal counsel.

More here: https://about.netflix.com/en/news/netflix-to-acquire-warner-bros

Former FDA, CRO, and Industry Leader Dr. Stephine Keeton Joins MMS as Senior Director of Biometrics

MMS, a global, data-focused clinical research organization (CRO), announced today that Stephine Keeton, PhD, has joined the company as Senior Director of Biometrics. Her appointment comes against an industry backdrop of rising trial and data complexity, alongside intensifying pressure on sponsors to accelerate cycle times and enhance productivity. With experience spanning regulatory, biopharma, and CRO environments, Dr. Keeton is uniquely positioned to strengthen MMS’ specialist biometrics capabilities and support sponsors in addressing today’s expanding clinical data challenges. Immediately prior to joining MMS, she led biostatistics at Altimmune, a clinical-stage biopharmaceutical company, and has previously served within the FDA in statistical roles for more than seven years.

“Stephine’s expansive experience across diverse settings will add significant value to our biometrics leadership team, in turn delivering value to our global biopharmaceutical clients,” said Chris Schoonmaker, Chief Operating Officer at MMS. “Her appointment comes at an inflection point for our industry, as sponsors increasingly look for specialized partners who can guide them through complex data challenges and deliver high-quality, submission-ready results.”

Michelle Gayari, Executive Vice President of Global Operational Excellence and Innovation added, “Stephine’s leadership will help us continue to advance our approach to biometrics, including integration of AI and automation across the data lifecycle, and partner with our clients to achieve their development goals.”

MMS delivers end-to-end biometrics solutions, integrating biostatistics, statistical programming, data management, data science, medical writing, and pharmacovigilance to support sponsors from trial design through regulatory submission.

Dr. Keeton said, “I am excited to join MMS at a time when the role of biometrics in clinical development is more critical than ever, and the opportunities to innovate are vast. Throughout my career, I’ve seen firsthand how the combination of thoughtful statistical planning, robust data strategy, and regulatory foresight shapes the success of clinical trials. I’m looking forward to working with a team that is so deeply committed to scientific excellence and operational innovation, and to helping our clients reduce their risk while accelerating the development of new therapies.”

With a global footprint across four continents, MMS anchors its biometrics solutions in quality-by-design and proactive data risk management, complemented by deep capabilities in trial design and regulatory strategy. Leveraging advanced technologies, including Datacise ® for real-time data visualization and analytics, and KerusCloud ® for clinical trial simulation and design optimization, MMS equips sponsors with the insights needed to maintain data integrity, anticipate risk, and ensure regulatory readiness at every stage. This holistic approach brings deep expertise, optimized processes, and advanced technologies to deliver the flexibility and strategic support sponsors need to thrive in an increasingly demanding data and regulatory environment.

Dr. Keeton’s appointment further strengthens MMS’ leadership as a data-focused CRO, and reinforces the company’s mission to support the development of therapies that make a meaningful difference for patients.

To learn more about biometrics solutions at MMS, visit https://mmsholdings.com/solutions/full-service-biometrics/.

About MMS

MMS Holdings (MMS) is an award-winning, data-focused clinical research organization (CRO) that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, a 19-year track record, AI technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner. With a global footprint across five continents, MMS maintains an industry-leading customer satisfaction rating. For more information, visit www.mmsholdings.com.

PumasAI’s AskPumas Surpasses 15,000 Questions Answered as Global Use of AI Tools in Drug Development Accelerates

PumasAI, a science-first organization that turns data into life-saving decisions faster, announced today that AskPumas, its secure Retrieval Augmented Generation (RAG) tool built for clinical pharmacologists and pharmacometricians, has just surpassed 15,000 questions answered.

AskPumas is an AI assistant that delivers trusted, on-demand access to field-specific knowledge by integrating a curated list of sources, giving pharmacometricians and clinical pharmacologists accurate, source-backed answers grounded in validated content.

“AskPumas was built for scientists who need answers they can stand behind, and this milestone signals the growing confidence of scientists in using artificial intelligence in drug development,” said Dr. Vijay Ivaturi, Co-Founder and CEO of PumasAI. “We focused on real scientific workflows and created something dependable that our friends and colleagues would actually use. That is why we are seeing adoption grow rapidly.”

The AI needed in pharma and biotech

AskPumas is part of a broader AI strategy at PumasAI to help teams access insights quicker in a safe and repeatable way. Upcoming workflow automation features will continue to extend its value across model-informed drug development teams.

Key features of AskPumas include the following:

  • Curated Knowledge Resources: Through its constantly updated, focused resource base, the tool provides more relevant answers than generic large language models (LLMs).
  • Improved Accuracy: By focusing on reducing hallucinations and ensuring human verification of AI responses, AskPumas provides reliable, source-backed information.
  • Language Flexibility: Users can gain responses in multiple languages, and the system translates all PumasAI tutorials and documentation with ease.

“AskPumas is doing what pharmacometricians have always needed, supporting their work with fast and accurate access to curated knowledge relevant to the pharmacometrician,” said Dr. Andreas Noack, VP of Product Development at PumasAI.

More than 1,400 scientists across 260 institutions are now using PumasAI tools. The company continues to support innovation in academia by offering its solutions at no cost to academic institutions worldwide. Universities and academic researchers can gain free access to PumasAI tools by following the instructions at https://pumas.ai/our-products/pumas-for-academia.

To learn more or request a demo of AskPumas, visit https://pumas.ai/ or watch the video at https://youtu.be/LxY2ofCVX8E?si=dcS7HIgv5YaelmgE&t=232.

About PumasAI

PumasAI is an award-winning global healthcare intelligence company with a vision to accelerate precision healthcare to patients. Proprietary software and AI tools developed by the company include an integrated modeling and simulation platform designed to multiply productivity across the drug development lifecycle as well as a range of specialized solutions for data analytics, machine learning, clinical trial optimization, and regulatory compliance. Scientists at PumasAI partner with leading pharmaceutical innovators, providing expert consulting in clinical pharmacology, model-informed drug development (MIDD), pharmacometrics, front-end applications, and more. By streamlining modeling, simulation, and data analytics, their solutions empower scientists and pharmaceutical partners to accelerate breakthroughs and deliver transformative healthcare. For additional information, visit www.pumas.ai.

Respected Data Science Industry Leader Chris Hurley Joins TrialAssure Advisory Leadership Team to Strengthen Data Strategy and Innovation

CANTON, Mich. (December 2, 2025) – TrialAssure, a leading technology provider advancing clinical trial transparency, disclosure, and data sharing, announced today that Chris Hurley, MBA, Americas Director for PHUSE and former Director of Data Science at MMS, has joined TrialAssure’s Advisory Leadership Team. In this role, Hurley will provide strategic guidance on the company’s data strategy and help shape the future of TrialAssure’s technology platforms and analytics capabilities.

Hurley brings more than 35 years of experience across clinical data workflows, SAS programming, and regulatory submission support. As Director of Data Science at MMS, he led cross-functional initiatives that bridge programming, statistics, and automation. His ability to translate technical processes into scalable, business-ready solutions makes him a strong addition to TrialAssure’s advisory group as the company continues to expand its footprint in AI-powered pharma and biotech industry tools.

“Chris has a unique combination of deep technical experience and an intuitive understanding of how data can accelerate smarter, faster decision-making across the drug development lifecycle,” said Prasad M. Koppolu, Chief Operating Officer (COO) at TrialAssure. “His contributions will help us evolve our platform strategy to meet the needs of global sponsors, regulators, and patients.”

Hurley entered the pharmaceutical industry in 1990 at Warner-Lambert/Parke-Davis, which later became part of Pfizer, and has held leadership roles across both Sponsor and CRO settings. Recognized throughout the industry for his technical leadership and collaborative approach, Hurley is known for his mentorship, process development, and active engagement in global forums.

“I’m excited to join TrialAssure’s Advisory Leadership Team and contribute to its mission of building smarter tools for the life sciences industry,” said Hurley. “Data strategy is critical to innovation in clinical research, and TrialAssure is leading the charge with anonymization and generative AI technology that makes a measurable impact.”

TrialAssure continues to expand its advisory network with respected leaders across regulatory science, medical writing, AI, and clinical operations. Hurley’s appointment reflects the company’s ongoing investment in expert-driven growth and innovation.

To learn more about TrialAssure solutions, visit https://www.trialassure.com/software/.

ABOUT TRIALASSURE

TrialAssure® is an award-winning global data transparency company providing fast, intelligent, and cost-effective software and services for the pharmaceutical industry and related sectors. A recognized leader in artificial intelligence (AI) and machine learning (ML), TrialAssure offers AI Enabled, Human Driven™ solutions that support compliance through document and data anonymization, AI-assisted content development, compliance tracking, and clinical trial disclosure. Founded in 2009, TrialAssure’s global team builds proven technology platforms that help Sponsors and research organizations stay aligned with transparency regulations worldwide. TrialAssure was named Data Solution of the Year by the Data Breakthrough Awards.

For more information, visit www.trialassure.com

Hemmings Announces 40 Percent Reduced Buyer’s Fees on Select Auctions for Cyber Monday

0

A curated lineup of auctions goes live Nov. 24 and ends Dec. 1

CHARLOTTE, NC/BENNINGTON, VT (November 20, 2025) — Hemmings, the world’s largest online, collector car marketplace, today announced its Cyber Monday collector car deal of the year, offering a 40 percent discount on buyer’s fees for select Hemmings Auctions. Eligible auctions launch on Monday, November 24 and close on Monday, December 1, 2025.

Just in time for the holiday season, this special offer gives automotive enthusiasts the chance to bid on a curated lineup of standout collector vehicles, ranging from early hot rods and American muscle to rare European classics and offroad icons.

“Cyber Monday gives us a chance to welcome new buyers into the Hemmings experience,” said Jonathan Shaw, President of Hemmings. “The reduced buyer’s fee opens the door to discover exceptional vehicles and enjoy our marketplace at its best.”

Hemmings Cyber Monday Offer Details

  • The Offer: 40 percent off the standard buyer’s fee (5%) for select Hemmings Auctions, reducing the buyer’s fee to 3% for one day only.
  • The Auctions: Eligible auctions launch on Monday, November 24, 2025 and close on December 1, 2025, highlighted at https://www.hemmings.com/ by special badging on the auction’s lead image.
  • How to Participate: Buyers must register to bid by creating a FREE Hemmings account at hmn.com/cybermonday

About Hemmings

Founded in 1954, Hemmings is the world’s largest online collector car marketplace. For more than 70 years, we have grown and uplifted the collector car community because we’ve been part of it since the start. Through our frictionless marketplace, quality entertainment, and professional service, we help all willing drivers buy, sell, and live the collector car lifestyle. Hemmings Motor Club extends this mission by bringing enthusiasts together through exclusive benefits, curated driving experiences, and deeper community connections for those who live to drive. More information, services, and content are available at https://www.hemmings.com/. Stay connected with Hemmings on Facebook, Instagram, and YouTube, and search tens of thousands of vehicle listings from the palm of your hand with the Hemmings App.




MMS Brings Biometrics and AI Leadership to PHUSE EU Connect 2025 and Previews Accepted Presentations for US Connect 2026

0

MMS, a global, data-focused clinical research organization (CRO), is set to bring fresh insights and hands-on engagement to PHUSE EU Connect 2025, taking place in Hamburg, Germany, from November 16-19, 2025, at CCH – Congress Center Hamburg.

James Zee, Director of Statistical Programming at MMS, will deliver the presentation “Rethinking Automation in the AI Era” on Wednesday, November 19 at 12:00 PM, as part of the Machine Learning, AI, and LLM stream (Paper ML13). The session will explore through specific use cases how intelligent automation and artificial intelligence alongside human expertise are already accelerating drug development and improving quality. Zee will draw on his experience working directly with advanced technologies such as Datacise ®, an innovative, cloud-based technology platform from MMS that enables biotechnology and pharmaceutical companies to more efficiently curate, analyze, and visualize clinical and real-world data to accelerate decision-making.   

Additionally, MMS will host a new interactive game, Rooftop Runner – Conquer Your Clinical Challenges!, at exhibit booth 22. Attendees are invited to test their data instincts, compete for a high score, and enter to win Amazon vouchers, all while learning how MMS simplifies complexity through intuitive visualizations and data-first technology.

Looking Ahead to PHUSE US Connect 2026

MMS is also excited to announce that three abstracts have been accepted for the upcoming PHUSE US Connect 2026, taking place March 22–26, 2026 in Austin, Texas. Topics will explore the evolving role of AI in biometrics, and the importance of cross-functional collaboration to drive better outcomes.

MMS’ presentations include the following:

  • Building Cross-Functional Regulatory and Programming Alignment for Successful Submissions – Ben Kaspar, VP of Regulatory Strategy, and James Zee, Director of Statistical Programming, MMS
  • What Pharma Can Learn from Data Science Outside the Industry – Kris Wenzel, Sr. Manager of Data Science, MMS
  • Estimand-Aligned Multiple Imputation Strategies in CNS Trials with Complex Intercurrent Events – Veera Thota, Manager, Statistical Programming, MMS

Meet the MMS Team in Hamburg

Attendees at this year’s PHUSE EU Connect 2025 are encouraged to attend James Zee’s talk, stop by the MMS booth to experience Rooftop Runner, and connect with our biometrics leaders who are shaping the future of efficient, compliant, and data-driven clinical research.

To connect with any of the presenters or to schedule a meeting, visit https://mmsholdings.com/contact/.

About MMS

MMS Holdings (MMS) is an award-winning, data-focused clinical research organization (CRO) that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, a 19-year track record, AI technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner. With a global footprint across five continents, MMS maintains an industry-leading customer satisfaction rating.

For more information, visit www.mmsholdings.com.

Cliniphai and Nested Knowledge Announce Partnership at ISPOR Europe 2025 to Accelerate Global Health Technology Assessment (HTA) Dossier Localization with AI

Cliniphai, an AI Agent and Framework platform purpose-built to solve complex challenges in life sciences, announced a strategic partnership with Nested Knowledge, a leader in evidence review technology, today to streamline and accelerate the preparation and submission of localized Health Technology Assessment (HTA) dossiers globally. The partnership was formalized during the ISPOR Europe 2025 conference at the Scottish Event Campus in Glasgow this week.

This collaboration will combine Cliniphai’s localization platform, Athena, and its strategic partner Gibson Research Consultancy (GRC), a global leader in linguistic validation and user-centered research, to deliver AI-enabled human-in-the-loop (HITL) translations for dossier components from Nested Knowledge’s powerful systematic evidence synthesis platform.

Together, the companies are solving a critical bottleneck in HTA dossier localization by delivering the following:

  • AI-powered evidence synthesis through Nested Knowledge’s systematic literature review and indirect treatment comparison tools.
  • Expert-led, HITL translations via Cliniphai’s Athena platform and GRC-vetted linguists.
  • Rapid adaptation of HTA dossiers to meet the needs of global health authorities.
  • Improved accuracy and compliance through built-in regulatory alignment and operational transparency.

“Our goal is to help our clients accelerate study startup activities, and deliver needed therapies to patients worldwide,” said Jason Martin, MS, co-founder and Chairman at Cliniphai. “Partnering with Nested Knowledge allows us to dramatically reduce the time required to translate clinical evidence into HTA submissions and adapt them for various global requirements, utilizing our compliant GRC-based talent model. This efficiency is crucial for navigating complex regulatory landscapes.”

The partnership addresses the complexity and time burden of adapting comprehensive HTA dossiers for different regulatory bodies and local languages worldwide. By leveraging the AI and machine-learning capabilities of the Nested Knowledge platform, the companies will rapidly enhance the core evidence synthesis (SLRs and ITCs). Crucially, Cliniphai then utilizes its platform to engage a network of GRC-vetted local regulatory and specialized linguists to ensure rapid, accurate, and compliant localization of these complex documents.

Keith Kallmes, co-founder and President of Nested Knowledge, added “Cliniphai has built an exciting modern platform to expand the capabilities that Nested Knowledge is providing its customers. By integrating Cliniphai’s AI-accelerated localization platform and language expertise from GRC with our data synthesis tools, we are jointly empowering life science companies to create high-quality HTA dossiers with unprecedented speed. This partnership is a force multiplier for helping companies looking to accelerate the translations and preparations of their HTAs to support market access.” To schedule a call to learn more, visit: https://cliniphai.com/contact-us/.